Is HIMS Stock Ready For A Rebound After A 60% Fall? [Forbes]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Forbes
Long-term investors may find this familiar—HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it dropped 77%. Amid shortages of weight loss drugs from Eli Lilly and Novo Nordisk, HIMS benefited by offering compounded versions. Now that supply constraints have eased, HIMS has transitioned to offering branded medications through its telehealth services, including Eli Lilly's in-demand Zepbound. For those seeking upside with lower volatility than individual stocks, take a look at the High-Quality portfolio which has beaten the S&P 500 with returns exceeding 91% since its inception. HIMS numbers tell a compelling story: Revenue has grown at an average of 76.2% annually over the past three years Revenue surged 69.3% in the past year, climbing from $872 million to $1.5 billion Operating margins remain modest at 4%, but adjusted EBITDA margin is 12%, and cash margins are 17% Debt levels are minimal (debt-to-equity
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (NYSE:LLY) had its price target lowered by analysts at Bank of America Corporation from $1,286.00 to $1,268.00. They now have a "buy" rating on the stock.MarketBeat
- Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $951.00 to $1,145.00. They now have a "buy" rating on the stock.MarketBeat
- Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win [Yahoo! Finance]Yahoo! Finance
- Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/8/25 - Form 3
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- LLY's page on the SEC website